Comparative Effects of and Berberine on Adipokines, Body Composition, and Metabolic Parameters in Obese Patients: A Randomized Study.

Noemí Cárdenas-Rodríguez, Jazmín Carro-Rodríguez, Iván Ignacio-Mejía, Cindy Bandala, Eleazar Lara-Padilla, Felipe Muñoz-González, Itzel Peña-Montero, Modesto Gómez-López, Ana Paola Hernández-Roldán, Juan Carlos Huerta-Cruz, Brayan Domínguez

Journal: Nutrients 2024;16(14):

PMID: 39064727

Abstract

UNLABELLED

(GS) and berberine (BBR) are natural products that have demonstrated therapeutic potential for the management of obesity and its comorbidities, as effective and safe alternatives to synthetic drugs. Although their anti-obesogenic and antidiabetic properties have been widely studied, comparative research on their impact on the gene expression of adipokines, such as resistin (Res), omentin (Ome), visfatin (Vis) and apelin (Ap), has not been reported.

METHODOLOGY

We performed a comparative study in 50 adult Mexican patients with obesity treated with GS or BBR for 3 months. The baseline and final biochemical parameters, body composition, blood pressure, gene expression of Res, Ome, Vis, and Ap, and safety parameters were evaluated.

RESULTS

BBR significantly decreased ( < 0.05) body weight, blood pressure and Vis and Ap gene expression and increased Ome, while GS decreased fasting glucose and Res gene expression ( < 0.05). A comparative analysis of the final measurements revealed a lower gene expression of Ap and Vis ( < 0.05) in patients treated with BBR than in those treated with GS. The most frequent adverse effects in both groups were gastrointestinal symptoms, which attenuated during the first month of treatment.

CONCLUSION

In patients with obesity, BBR has a better effect on body composition, blood pressure, and the gene expression of adipokines related to metabolic risk, while GS has a better effect on fasting glucose and adipokines related to insulin resistance, with minimal side effects.

Address: Laboratorio de Neurociencia Traslacional Aplicada a Enfermedades Crónicas y Emergentes, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City 11340, Mexico.; Laboratorio de Neurociencias, Instituto Nacional de Pediatría, Mexico City 04530, Mexico.; Laboratorio de Obesidad, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City 11340, Mexico.; Unidad de Investigación en Farmacología, Instituto Nacional de Enfermedades Respiratorias, Ismael Cosio Villegas, Secretaria de Salud, Mexico City 14080, Mexico.; Laboratorio de Neurociencia Traslacional Aplicada a Enfermedades Crónicas y Emergentes, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City 11340, Mexico.; Laboratorio de Diseño y Desarrollo de Nuevos Fármacos e Innovación Biotecnológica, Mexico City 11340, Mexico.; Laboratorio de Medicina Traslacional, Escuela Militar de Graduados en Sanidad, Universidad del Ejército y Fuerza Aérea, Mexico City 11200, Mexico.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.